Discuva’s strategy addresses the current unmet urgent need to identify new drug treatment options to combat infections caused by Multidrug-resistant (MDR) Gram negative and Gram positive pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae Escherichia coli, Neisseria gonorrhoeae, Staphlococcus aureus and Enterococcus sp.
Discuva’s objectives are to progress disease-targeted antibacterial drugs from its proprietary biology platforms through to the market both with and without collaborative partners.
Discuva’s SATIN technology is applied on bacteriocidal hits identified from high-throughput phenotypic screening to identify both the molecular target(s) of each compound and all the corresponding potential resistance gene(s). The information from SATIN enables the prioritisation of compounds into chemical optimisation which ultimately have the best chance of clinical success.
The successful application of the SATIN technology is allowing Discuva to progress multiple novel compound series through chemical optimisation.